We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+42.53%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.08B
AUM Growth
+$924M
Cap. Flow
+$456M
Cap. Flow %
14.8%
Top 10 Hldgs %
38.34%
Holding
121
New
53
Increased
26
Reduced
7
Closed
25

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$122M
2
LLY icon
Eli Lilly
LLY
+$121M
3
MRVI icon
Maravai LifeSciences
MRVI
+$96M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$78.7M
5
AVTR icon
Avantor
AVTR
+$51.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$104M
2
MRK icon
Merck
MRK
+$94.9M
3
BIIB icon
Biogen
BIIB
+$81.3M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$67.1M
5
TMO icon
Thermo Fisher Scientific
TMO
+$52.2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.07%
2 Technology 1.87%
3 Financials 0.18%
4 Industrials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLSA
76
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$5.57M 0.18%
+500,000
New +$5.36M
NAUT icon
77
Nautilus Biotechnolgy
NAUT
$132M
$5.42M 0.18%
+500,000
New +$5.27M
OCUL icon
78
Ocular Therapeutix
OCUL
$1.83B
$5.17M 0.17%
+250,000
New +$3.71M
OBIO icon
79
Orchestra BioMed
OBIO
$228M
$5.12M 0.17%
400,000
– –
FPRX
80
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$5.1M 0.17%
+300,000
New +$3.76M
PHAT icon
81
Phathom Pharmaceuticals
PHAT
$928M
$5.07M 0.16%
+152,500
New +$6.18M
ALBO
82
DELISTED
Albireo Pharma Inc
ALBO
$4.69M 0.15%
+125,000
New +$4.55M
MLTX icon
83
MoonLake Immunotherapeutics
MLTX
$1.56B
$4.55M 0.15%
+400,000
New +$4.25M
SNCE
84
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$4.27M 0.14%
+20,000
New +$4.16M
PANA.U
85
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$3.83M 0.12%
300,000
– –
TNGX icon
86
Tango Therapeutics
TNGX
$4.21B
$3.43M 0.11%
300,000
– –
ITOS
87
DELISTED
iTeos Therapeutics
ITOS
$3.13M 0.1%
92,574
-237,426
-72% -$6.29M
KROS icon
88
Keros Therapeutics
KROS
$197M
$2.82M 0.09%
+40,000
New +$2.52M
RCKT icon
89
Rocket Pharmaceuticals
RCKT
$343M
$2.74M 0.09%
+50,000
New +$1.82M
ANNX icon
90
Annexon
ANNX
$796M
$1.75M 0.06%
70,000
+32,430
+86% +$835K
ACCD
91
DELISTED
Accolade Inc
ACCD
$1.74M 0.06%
40,000
– –
BCAB icon
92
BioAtla
BCAB
$5.34M
$1.7M 0.06%
+1,000
New +$1.67M
NRIX icon
93
Nurix Therapeutics
NRIX
$2.45B
$1.64M 0.05%
50,000
– –
AMWL icon
94
American Well
AMWL
$180M
$1.27M 0.04%
2,500
– –
RLAY icon
95
Relay Therapeutics
RLAY
$4B
$1.25M 0.04%
30,000
– –
INZY
96
DELISTED
Inozyme Pharma
INZY
$200K 0.01%
9,683
-52,172
-84% -$1.24M
ACIU icon
97
AC Immune
ACIU
$231M
– –
-1,550,000
Closed -$7.56M
ADAP
98
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-2,084,700
Closed -$16.6M
AKBA icon
99
Akebia Therapeutics
AKBA
$338M
– –
-7,324,000
Closed -$18.4M
AMRN
100
Amarin Corp
AMRN
$297M
– –
-225,300
Closed -$19M
1 2 3
4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2020 Portfolio in Review

As of Q4 2020, Avidity Partners Management held 121 positions worth $3.08B, up 43% from $2.16B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Avidity Partners Management deployed $456M of net new capital in Q4 2020, opening 53 new positions and adding to 26 existing holdings. Its largest new stake was AstraZeneca: 1,150,000 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 80% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $67.1M trimmed.

  • Avidity Partners Management's largest Q4 2020 buy was AstraZeneca: 1,150,000 shares worth $115M.
  • Avidity Partners Management added most to Avantor in Q4 2020, an estimated $51.7M increase.
  • Avidity Partners Management's biggest Q4 2020 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $67.1M.
  • Avidity Partners Management fully exited Seagen Inc. Common Stock in Q4 2020, selling an estimated $104M.
  • Avidity Partners Management's ten largest holdings make up 38% of its $3.08B portfolio in Q4 2020.
  • Avidity Partners Management opened 53 new positions and closed 25 in Q4 2020.
  • Avidity Partners Management's portfolio value rose 43% quarter-over-quarter to $3.08B.

Based on Avidity Partners Management's 13F filing for Q4 2020, filed 16 Feb 2021.